OPA1-15483 detects BRS3 from human samples.
OPA1-15483 has been successfully used in immunohistochemistry procedures. By immunohistochemistry, OPA1-15483 detects BRS3 in formalin fixed, paraffin embedded human tissues.
The OPA1-15483 immunogen is a synthetic peptide (KLH conjugated) corresponding to the C-terminal domain of BRS3.
BRS3 expression has been reported in lung (normal and cancer), nasal mucosa, placenta, and uterus. ESTs have been isolated from normal brain and kidney cancer libraries.
G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: bombesin like receptor 3; Bombesin receptor subtype-3; bombesin-like receptor 3; BRS 3; BRS-3; G-protein coupled receptor
Gene Aliases: BB3; BB3R; BRS3
UniProt ID: (Human) P32247
Entrez Gene ID: (Human) 680